This site uses cookies to deliver our services and to show you relevant ads and presentations. By clicking on "Accept", you acknowledge that you have read and understand our Cookie Policy , Privacy Policy , and our Terms of Use.
X

Download Screening for Prostate Cancer PowerPoint Presentation


Login   OR  Register
X


Iframe embed code :



Presentation url :

X

Description :

Available Screening for Prostate Cancer powerpoint presentation for free download which is uploaded by search an active user in belonging ppt presentation Health & Wellness category.

Tags :

Screening for Prostate Cancer

Home / Health & Wellness / Health & Wellness Presentations / Screening for Prostate Cancer PowerPoint Presentation

Screening for Prostate Cancer PowerPoint Presentation

Ppt Presentation Embed Code   Zoom Ppt Presentation

About This Presentation


Description : Available Screening for Prostate Cancer powerpoint presentation for free download which is uploaded ... Read More

Tags : Screening for Prostate Cancer

Published on : Feb 24, 2014
Views : 491 | Downloads : 0


Download Now

Share on Social Media

             

PowerPoint is the world's most popular presentation software which can let you create professional Screening for Prostate Cancer powerpoint presentation easily and in no time. This helps you give your presentation on Screening for Prostate Cancer in a conference, a school lecture, a business proposal, in a webinar and business and professional representations.

The uploader spent his/her valuable time to create this Screening for Prostate Cancer powerpoint presentation slides, to share his/her useful content with the world. This ppt presentation uploaded by onlinesearch in this Health & Wellness category is available for free download,and can be used according to your industries like finance, marketing, education, health and many more.

SlidesFinder.com provides a platform to marketers, presenters and educationists along with being the preferred search engine for professional PowerPoint presentations on the Internet to upload their Screening for Prostate Cancer ppt presentation slides to help them BUILD THEIR CROWD!!

User Presentation
Related Presentation
Free PowerPoint Templates
Slide 1 - CARCINOMA DELLA PROSTATA
Slide 2 - PROSTATE CANCER Prostate Anatomy
Slide 3 - Prostate cancer is a disease predominantly of the older male population. Autopsy series have indicated that 15% to 30% of men older than the age 50 years have histologic evidence of prostate cancer
Slide 4 - PROSTATE CANCER DEATHS BY AGE
Slide 5 - ppt slide no 5 content not found
Slide 6 - ppt slide no 6 content not found
Slide 7 - ppt slide no 7 content not found
Slide 8 - ppt slide no 8 content not found
Slide 9 - Risk Factors for Prostate Cancer Age – Found mainly in men over age 55. Average age of diagnosis is 70 Family History – Men’s risk is higher if father or brother is diagnosed before the age of 60 Race – Prostate cancer is found more often in African American men then White men. It is less common in Asian and American Indian men Dietary factors – Evidence suggests that a diet high in fat may increase the risk of prostate cancer and diets high in fruits and vegetables decrease the risk
Slide 10 - Risk for Developing Prostate Cancer
Slide 11 - Genetic alterations associated with progression of prostate cancer
Slide 12 - Hypothalamus pituitary testicular axis
Slide 13 - Detailed schematic: Lateral section of a normal prostate
Slide 14 - PROSTATE CANCER Stage A : Deep tumor: may not be detected by digital-rectal exam Stage B: Tumor may be detected by DRE or ultrasound Stage C: Spread to surrounding tissue Stage D: Metastasis to bone and lymph nodes
Slide 15 - ppt slide no 15 content not found
Slide 16 - The Gleason grading system is used to evaluate or grade prostate cancer cells obtained by needle biopsy. The cells are assigned a number between 1 and 5 nearly normal cells are grade 1, and the most abnormal are grade 5. The scores of the two most common cell patterns are added together. Gleason scores range from 2 to 10. The higher the grade, the more aggressive the cancer. The Gleason scoring system for prostate cancer.
Slide 17 - ppt slide no 17 content not found
Slide 18 - Prostatic Intraepithelial Neoplasia 85% carcinomas have associated PIN High grade PIN has 30-50% risk of CA on subsequent biopsies cf 13% in controls PIN does not cause elevated PSA Atypical foci in 3-5% of biopsies, 50% risk of cancer on repeat biopsy
Slide 19 - Symptoms of Prostate Cancer Frequent urination Inability to urinate Trouble starting and stopping urination Blood in the urine or semen Painful ejaculation Painful or burning urination
Slide 20 - Screening for Prostate Cancer Prostate-Specific Antigen Blood Test (PSA) – Measures substance made by the prostate gland Digital Rectal Exam (DRE) – Physical exam of the Prostate Gland Transrectal Ultrasound (TRUS) – Uses sound waves to make an image of the prostate on a video screen
Slide 21 - Screening … For & Against Organ confined prostate cancer is curable Advanced prostate cancer is incurable Screening offers earlier diagnosis Early detection is our only hope for mortality reduction More men die with Prostate cancer than of it PSA test not accurate enough Biopsy and treatment may cause morbidity No trial to show mortality reduction
Slide 22 - ppt slide no 22 content not found
Slide 23 - ppt slide no 23 content not found
Slide 24 - Factors Increasing PSA Cycling Prostate massage Cystoscopy Ejaculation Prostate biopsy Transrectal Ultrasound Prostate disease
Slide 25 - Percentage risk of CaP
Slide 26 - Screening - Improving the PSA PSA Velocity > 0.75 ng/ml/yr PSA Density Age adjusted PSA Molecular forms- free / total PSA
Slide 27 - PSA Isoforms Free and complexed PSA - ACT FREE / TOTAL ratio < 10% suggestive Complex now measurable
Slide 28 - Digital Rectal Exam for Prostate Tumors
Slide 29 - Transrectal ultrasound-guided biopsy of the prostate
Slide 30 - ppt slide no 30 content not found
Slide 31 - Management Alternatives Expectant -- Watchful Waiting Radical Prostatectomy Radiation Therapy -- EBRT, 3D - CRT, Brachytherapy: HDR, Seed Hormonal -- Mono Rx, MAB Combination
Slide 32 - Trans-urethral Resection
Slide 33 - ppt slide no 33 content not found
Slide 34 - Prostate CancerTreatment Paradigms Clinically Localized Hormone Refractory Local treatment Endocrine Chemotherapy Relapsed and Newly diagnosed M+
Slide 35 - Prostate Cancer Treatment Background 50% fail after local treatment 10-15% have distant metastasis at presentation Virtually all progress after endocrine treatment Chemotherapy used for symptomatic control No survival advantage in phase-III trials
Slide 36 - Endocrine control of prostate cancer
Slide 37 - Strategies for Androgen Deprivation LHRH = Luteinizing hormone-releasing hormone 5  R = 5-alpha reductase. LH = Luteinizing hormone AR = Androgen receptor T = Testosterone DHT = Dihydrotestosterone.
Slide 38 - Types of Androgen Deprivation
Slide 39 - Side Effects of Androgen Deprivation
Slide 40 - Adjuvant trials. SWOG 9921: adjuvant androgen deprivation versus mitoxantrone plus prednisone plus androgen deprivation in selected high-risk prostate cancer patients following radical prostatectomy, phase III. Prior neoadjuvant therapy is permitted if the duration is 4 months or less and if clinical criteria (PSA 15 ng/mL or biopsy GS    7 or PSA   10 ng/mL and GS   6) are satisfied prior to surgery.
Slide 41 - Adjuvant trials. RTOG 99-02: phase III protocol of androgen suppression (AS) and radiation therapy (RT) versus AS and RT followed by chemotherapy with paclitaxel, estramustine, and etoposide for localized high-risk prostate cancer.
Slide 42 - Adjuvant hormonal therapy. Survival improvements were noted only in one trial conducted by the European Organization for Research and Treatment of Cancer with the use of adjuvant hormonal therapy. (Adapted from Bolla et al.)
Slide 43 - Adjuvant hormones. Adjuvant hormones after radical prostatectomy have demonstrated survival enhancement in patients with pathologically positive lymph nodes. (Adapted from Messing et al.
Slide 44 - SWOG Intergroup 0162 trial of continuous versus intermittent androgen deprivation
Slide 45 - Hormone-independent prostate cancer. The development of hormonal escape is depicted. Despite a high initial response rate to androgen deprivation, essentially all men will fail and progress to androgen independence and ultimately hormone refractory status. Treatment for patients with hormone-refractory prostate cancer must be tailored individually, and take into account the need to maintain quality of life in this terminal stage of the disease. Antiandrogen withdrawal, second-line hormonal therapy, palliative supportive care measures including radiation therapy (external or systemic) and pain control, and chemotherapy are all valid options.
Slide 46 - Mitoxantrone + Steroids Versus Steroids Alone Table of randomized chemotherapy trials in metastatic disease. Although chemotherapy has not demonstrated an impact on survival yet, the use of mitoxantrone and steroids has, however, demonstrated a significant palliative effect in randomized trials
Slide 47 - SWOG trial of chemotherapy in metastatic disease. SWOG Intergroup 9916 randomized phase III study of docetaxel + estramustine versus mitoxantrone + prednisone in patients with hormone-refractory prostate cancer; 620 patients must be entered to detect a 33% survival difference. Future directions include exploring biologic therapies such as epithelial growth factor receptor inhibitors and antiangiogenesis strategies.
Slide 48 - Combined Androgen Deprivation Compared with Monotherapy in Advanced Prostate Cancer
Slide 49 - Docetaxel in HRPC Multiple phase II studies Responses in 45-82% (similar 95% CI duration) Estramustine based RR higher but more toxic Single agent data (weekly and every 3 wks) consistently safe and effective Superior to mitoxantrone + prednisone?
Slide 50 - TAX327 Study Design Stratification Pain level PPI ≥ 2 or AS ≥ 10 vs. PPI < 2 or AS < 10 KPS ≤ 70 vs. ≥ 80 Docetaxel 75 mg/m2 q3 wks + Prednisone 5 mg bid Mitoxantrone 12 mg/m2 q3 wks + Prednisone 5 mg bid R A N D O M I Z E Docetaxel 30 mg/m2 wkly 5 of 6 wks +Prednisone 5 mg bid Treatment duration in all 3 arms = 30 wks
Slide 51 - Overall Survival Median survival Hazard (mos) ratio P-value Combined: 18.2 0.83 0.03 D 3 wkly: 18.9 0.76 0.009 D wkly: 17.3 0.91 0.3 Mitoxantrone 16.4 – – Months 0 6 12 18 24 30 0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 Docetaxel 3 wkly Docetaxel wkly Mitoxantrone Probability of Surviving
Slide 52 - TAX 327 Docetaxel 3 Weekly Safe Significantly improves: – Survival (18.9 vs 16.5 months) 24% reduction in the risk of death (95% CI 0.62-0.94, p=.009) – PSA decline - 45% vs. 32%, p<.0005 – Pain response - 35% vs. 22%, p=.01 – Quality of life
Slide 53 - Prostate CancerTreatment Paradigms Clinically Localized Hormone Refractory Local treatment Docetaxel + P q3 wks Improves survival Endocrine Relapsed and Newly diagnosed M+
Slide 54 - Prostate CancerTreatment Paradigms Clinically Localized Hormone Refractory Local treatment Endocrine Docetaxel Relapsed and Newly diagnosed M+ ? ?
Slide 55 - Prostate CancerTreatment Paradigms Clinically Localized Hormone Refractory Local treatment Endocrine Mitoxantrone+P for symptoms Relapsed and Newly diagnosed M+ No Survival Benefit
Slide 56 - ppt slide no 56 content not found
Slide 57 - ppt slide no 57 content not found
Slide 58 - ppt slide no 58 content not found
Slide 59 - ppt slide no 59 content not found
Slide 60 - ppt slide no 60 content not found
Slide 61 - ppt slide no 61 content not found
Slide 62 - ppt slide no 62 content not found